Logo Image
|Videos|May 15, 2020

How Pharmacists Are Fighting COVID-19 Misinformation

Elizabeth Leung, PharmD, shares SIDP's educational efforts surrounding COVID-19 treatment.

Segment Description: Elizabeth Leung, PharmD,MSCI, BCPS-AQ ID, Co-lead, St. Michael’s Hospital Antimicrobial Stewardship Program,

University of Toronto talks about the work being done by the Society of Infectious Disease Pharmacists (SIDP), one of Contagion’s strategic partners.

More coverage featuring pharmacists on the frontlines:

Contagion Editor in Chief Jason Gallagher, PharmD, discusses the new authorization for Remdesivir.

Jeannette Bouchard, PharmD, infectious disease pharmacy fellow, University of South Carolina and Prisma Health, discusses how ID pharmacists are taking on new responsibilities and working collaboratively to respond to COVID-19.

Ryan W. Stevens, PharmD, BCIDP, discusses the risks associated with convalescent plasma and highlights what clinicians should know about using convalescent plasma among patients with COVID-19.

Lucas Schulz, PharmD, BCPS, AQ-ID, clinical coordinator, infectious diseases, University of Wisconsin Health, discusses how he is preparing for COVID-19 as a clinical pharmacist working in Wisconsin.

Thomas Dilworth, PharmD, pharmacy coordinator, infectious diseases, Aurora St. Luke’s Medical Center, provides a recap of ACEIs, ARBs, and NSAIDs in patients with COVID-19.

Related to this article

View more
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Read more
Measles Update: October 30, 2026
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Read more
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Read more
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Read more
Measles Update: October 23, 2026
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Read more
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Read more